Anabolic Steroids Detected in Bodybuilding Dietary Supplements– a Significant Risk to Public Health V
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Seco-Steroids C07C)
CPC - C07J - 2021.08 C07J STEROIDS (seco-steroids C07C) Definition statement This place covers: Compounds containing a cyclopenta[a]hydrophenanthrene skeleton (see below) or a ring structure derived therefrom: • by contraction or expansion of one ring by one or two atoms; • by contraction or expansion of two rings each by one atom; • by contraction of one ring by one atom and expansion of one ring by one atom; • by substitution of one or two carbon atoms of the cyclopenta[a]hydrophenanthrene skeleton, which are not shared by rings, by hetero atoms, in combination with the above defined contraction or expansion or not, or; • by condensation with carbocyclic or heterocyclic rings in combination with one or more of the foregoing alterations or not. Preparation of steroids including purification, separation, stabilisation or use of additives unless provided for elsewhere, as specified below. Treatment and modification of steroids provided that • the treatment is not provided for elsewhere and • the resultant product is a compound under the subclass definition. Relationships with other classification places In class C07, in the absence of an indication to the contrary, a compound is classified in the last appropriate place, i.e. in the last appropriate subclass. For example cyclopenta [a] hydrophenantrenes are classified in subclass C07J as steroids and not in subclasses C07C or C07D as carbocyclic or heterocyclic compounds. Subclass C07J is a function-oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in the IPC exist, for example: Subclass A01N: Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g. -
United States Patent (19) 11 Patent Number: 4,585,591 Nitta Et Al
United States Patent (19) 11 Patent Number: 4,585,591 Nitta et al. (45) Date of Patent: Apr. 29, 1986 (54) 17B-ETHYNYLSTEROIDs AND PROCESS 56) References Cited FOR PREPARNG SAME U.S. PATENT DOCUMENTS 75) Inventors: Issei Nitta, Machida; Shinichiro 3,023,206 2/1962 Burnet al. ..................... 260/239.55 Fujimori, Yokohama; Toshio Haruyama, Sagamihara; Shinya FOREIGN PATENT DOCUMENTS Inoue, Yamato, all of Japan 845441 8/1960 United Kingdom ............. 260/397.4 73 Assignee: Mitsubishi Chemical Industries, Ltd., OTHER PUBLICATIONS Tokyo, Japan L. A. van Dijck et al., "Synthesis and Reactions of 3-Methoxy-17-Hydroxy-17-Ethynyl-1,3,5(10)-Estra 21 Appl. No.: 325,026 triene', Recueil Journal of the Royal Netherlands Chemical Society, 96,7-8, Jul.-Aug., pp. 200-205 22 Filed: Nov. 25, 1981 (1977). Primary Examiner-Elbert L. Roberts 30 Foreign Application Priority Data Attorney, Agent, or Firm-Oblon, Fisher, Spivak, Dec. 10, 1980 JP Japan ................................ 55-174065 McClelland & Maier Dec. 10, 1980 JP Japan ... ... 55-174.066 Feb. 23, 1981 JP Japan .................................. 56-25307 (57) ABSTRACT Jul. 28, 1981 (JP) Japan ................................ 56-18343 This is disclosed novel intermediates, i.e. 1743-ethynyl steroids, which are useful for the preparation of corti 51) Int. Cl. .................................................. CO7J 1/00 coids such as hydrocortisone and prednisolone, and a 52 U.S. C. ............................ 260/3974; 260/397.45; process for preparing the same. 260/239.55 C, 260/397.5; 260/397.47 58) Field of Search ......................... 260/397.4, 397.45 4 Claims, No Drawings 4,585,591 1 2 17(3-ETHYNYLSTEROIDS AND PROCESS FOR -continued PREPARING SAME CECH BACKGROUND OF THE INVENTION This invention relates to a novel intermediate for use in the preparation of corticoids (adrenocortical hor mones) such as hydrocortisone, prednisolone and the MeO like. -
Steroidogenic Pathway Poster-COMPLEX-24X36
Cholesterol The Steroidogenic Pathways Congenital adrenal hyperplasia (CAH), Hyperglycemia, azole antifungals, aging, smoking, E2, progesterone, azole smoking, dioxin toxicity, HIV, licorice, Phytoestrogens, flaxseed, licorice, Alcohol, IL-6, abdominal obesity, DHEA, antifungals, spironolactone etomidate, liarozole progestins, tamoxifen forskolin (-) (-) (-) (+) Pregnenolone CYPc17 17-OH-Pregnenolone 17,20 Lyase DHEAA17βHSD ndrostenediol (+) Hyperglycemia, hyperinsulinemia, PCOS (ovary), stress, alcohol, antiepileptics (+) CAH, chronic ETOH ingestion, PCB toxicity, progestins, D D D (-) (-) D PCB toxicity, DHEA, antiepileptics isoflavonoids, metformin, troglitazone, trilostane HS Pregnanediol Pregnanetriol β HS HS 3 HS β β β 3 3 3 (+) Hyperadrenalism, hyperthyroidism, hyperinsulinemia, PCOS, IL-4 (+) and IL-13, IGF-1, forskolin Smoking, dioxin, isoflavones, flaxseed, procyanidins, flavonoids, EGCG, epilobium, vitamin C, anastrazole, etc; CYPc17 17,20 Lyase 17βHSD Progesterone 17-OH-Progesterone Androstenedione Testosterone chrysin, stinging nettles, (-) and other flavonoids; β 5 ketoconazole, metformin α (+) (+) 1 5 1 Sodium depletion, high prolactin More cortisol: Less cortisol: Etiocholanolone Obesity (esp. visceral), A Good insulin sensitivity, ro CAH, late-onset adrenal hyperplasia, primary adrenal CYP2 metabolic A CYP2 hyperthyroidism, ro 5 m Excess adipose, alcohol, zinc (-) insufficiency, ankylosing spondylitis, increased salt (-) syndrome, hypothyroid, m α DHT at reduced inflammation, atas a (+) deficiency, stress, cravings, resveratrol, -
GC/C/IRMS) Als Potentielle Untersuchungsmethode Zum Nachweis Einer Illegalen Anwendung Von 19-17 Βββ-Nortestosteron in Der Ebermast
Einsatz der Stabilisotopen-Massenspektrometrie (GC/C/IRMS) als potentielle Untersuchungsmethode zum Nachweis einer illegalen Anwendung von 19-17 βββ-Nortestosteron in der Ebermast Dissertation zur Erlangung des akademischen Doktorgrades der Naturwissenschaften an der Bergischen Universität im Fachbereich Mathematik und Naturwissenschaften Die Arbeit wurde in der Zeit vom 15. Mai 2003 bis 31.Dezember 2006 am Chemischen und Veterinäruntersuchungsamt in Freiburg angefertigt vorgelegt von Annette Mertineit-Heinz Wuppertal 2007 Diese Dissertation kann wie folgt zitiert werden: urn:nbn:de:hbz:468-20070870 [http://nbn-resolving.de/urn/resolver.pl?urn=urn%3Anbn%3Ade%3Ahbz%3A468-20070870] dem Allmächtigen Gott Das Geheimnis Gottes ist Jesus Christus, in dem alle Schätze der Weisheit und Erkenntnis verborgen sind. Die Bibel , Kolosser 2, 3 Dank Mein besonderer Dank gilt Herrn Prof. Dr. Michael Petz, der es mir ermöglichte, an der Universität Wuppertal diese Dissertation anzufertigen. Für seine Hilfsbereitschaft und Ermutigungen bin ich ihm sehr dankbar. Bedanken möchte ich mich beim Amtsleiter des CVUA Herrn Dr. Roland Renner sowie Laborleiter Herrn Dr. Martin Metschies, dass ich die Untersuchungen für diese Arbeit am CVUA durchführen durfte. Bei Laborleiterin Frau Dr. Eva Annweiler möchte ich mich für ihre vielseitige Unterstützung in analytischen Fragen und ihre Hilfe bei der Durchsicht der Arbeit bedanken. Den Labormitarbeitern Herrn Thomas Huber danke ich für die Unterstützung bei den EA/IRMS-Messungen, Frau Sylvia Scanlan-Sierra bei den GC/MS-Messung und Herrn Manfred Grosse bei den GC/FID-Messungen. Herr Grosse hat sich immer Zeit genommen, mich zu unterstützen, ohne dabei seine tägliche Arbeit zu vernach- lässigen. Für die Unterstützung der Aufarbeitung der Eberurine gilt mein Dank Laborleiter Herr Lippold und den Mitarbeitern Frau Annabarbara Fies, Herrn Markus Roth und Frau Maria Schmidt. -
United States Patent Office Patented Jan
3,231,567 United States Patent Office Patented Jan. 25, 1966 2 droxy ethylene, hydroxy propylene, hydroxybutylene and 3,231,567 PROCESS FOR THE PREPARATION OF 3-HY the like; a saturated or unsaturated cycloaliphatic moiety, DROXY. AND 3-ALKOXY-ESTRATRIENES such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, AND INTERMEDIATES THEREFOR cyclopentenyl, cyclohexenyl, cyclopentylpropyl, cyclo Alberto Ercoli and Rinaldo Gardi, Milan, and Cesare 5 heptyl, cyclooctyl radical; or an araliphatic moiety, such Pedrai, Bergamo, Italy, assignors to Francesco Wismara as benzyl, phenetyl, cynnamyl radical. Preferred hydro S.p.A., Casadenovo, Italy carbon radicals are aliphatic moieties containing from 1 No Drawing. Fied Dec. 16, 1963, Ser. No. 330,584 to 8 carbon atoms, inclusive, cycloaliphatic moieties con Claims priority, application Italy, Dec. 19, 1962, taining from 5 to 6 carbon atoms in the ring and the Patent 24,856/62 benzyl radical. 20 Claims. (C. 260-239.55) 10 Methods for the aromatization of the ring A of 19-nor This invention relates to an improved process for con steroids are already known in the literature and the prior verting steroids of the 19-nor-androstane and 19-nor-preg art teaches the conversion of a 3-keto-19-norsteroid of name series into derivatives of the estrogenic series. The the androstane series into a derivative of the estrogenic invention also relates to certain new 19-norsteroid deriva 5 series. This conversion may be accomplished by first tives useful as intermediates in said conversion. preparing a 5,10-epoxy-estren-3-one or a 3-ketal thereof More particularly, this invention is concerned with a by epoxiding a 5 (10)-estrene-3-one or A-3-keto-19-nor amethod for the aromatization of the ring A to produce steroid 3-ketal, respectively, with a peracid. -
Clinical, Morphological and Biochemical Studies of a Virilizing Tumor in the Testis
CLINICAL, MORPHOLOGICAL AND BIOCHEMICAL STUDIES OF A VIRILIZING TUMOR IN THE TESTIS Kenneth Savard, … , Edwin C. Hamblen, Frank L. Engel J Clin Invest. 1960;39(3):534-553. https://doi.org/10.1172/JCI104067. Research Article Find the latest version: https://jci.me/104067/pdf CLINICAL, MORPHOLOGICAL AND BIOCHEMICAL STUDIES OF A VIRILIZING TUMOR IN THE TESTIS * By KENNETH SAVARD,t RALPH I. DORFMAN, BILLY BAGGETT,t LINDA L. FIELDING, LEWIS L. ENGEL,§ HARRY T. McPHERSON, LEONARD M. LISTER,II DAVID S. JOHNSONA EDWIN C. HAMBLEN AND FRANK L. ENGEL (IProm the Worcester Foundation for Experimental Biology, Shrewsbury, Mass.; The John Collins Warren Laboratories, Collis P. Huntington Memorial Hospital of Harvard Uni- versity at Massachusetts General Hospital, and the Department of Biological Chem- istry, Harvard Medical School, Boston, Mass.; and the Departments of Medicine, Obstetrics and Gynecology, and Pathology, Division of Endocrinology, Duke University Medical Center, Durham, N. C.) (Submitted for publication May 18, 1959; accepted November 12, 1959) Although there is considerable indirect evidence such tumors cause elevated levels of urinary 17- indicating that virilizing testicular tumors exert ketosteroids. The morphology of these tumors their effects by producing androgenic steroid hor- leads one to predict that they are producing tes- mones, few attempts have been made to determine tosterone, since normal interstitial cells seem to the exact nature of the compounds produced. One have this function (22, 23). A few studies of the type of tumor which exerts particularly marked qualitative nature of the urinary steroids in pa- virilizing effects when found in prepubertal boys tients with this type of tumor seem to confirm such is that classified as an interstitial cell tumor of the a conclusion (13, 24). -
Recent Steroid Findings in “Designer Supplements”
In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (17). Sport und Buch Strauß - Köln 2009 M.K. Parr1), N. Haenelt1), G. Fußhöller1), U. Flenker1), H. Geyer1), G. Rodchenkov2), G. Opfermann1), W. Schänzer1) Recent steroid findings in “Designer Supplements” 1)Institute of Biochemistry, German Sport University, Cologne, Germany 2)Antidoping Centre Moscow, Moscow, Russia Abstract Several supplements have been purchased from two different internet-based suppliers and were analysed for their steroid content. Besides the findings of DHEA (and DHEA esters) products were found to contain 6-bromoandrostenedione, androstanoisoxazoles, and estra-4,9- diene-3,17-dione. Additionally Δ6-methyltestosterone was detected in the product “Jungle Warfare” from ALR Industries, androst-4-ene-3,11,17-trione in the product “11Oxo” from Ergopharm, and finally the product “Oxyguno” distributed by Spectra Force Research was found to contain 4-chloro- 11-oxomethyltestosterone. These three compounds have been reported in the 1960s to show weak androgenic (about ½ of testosterone) and from weak to strong anabolic properties. The urinary metabolism was studied following the administration of one capsule to one test person each. The administration of Δ6-methyltestosterone was detectable for more than one week by monitoring the metabolites 17α-hydroxy-17β-methylandrosta-4,6-dien-3-one, 17α-methyl-5β- androstane-3α,17β-diol, and 17β-methyl-5β-androstane-3α,17α-diol. Oral administration of androst-4-ene-3,11,17-trione resulted in several reduced metabolites with 11β- hydroxyandrosterone as main product. Isotope ratio mass spectrometry confirmed the exogenous origin of 11β-hydroxyandrosterone and 11β-hydroxyetiocholanolone as well as their 11-oxo precursors for up to 24 hours. -
Biological Efficacy and Plasma Norethisterone Levels of Orally Administered Norethisterone Enanthate in Rat and Hamster
Indian J Physiol Pharmacol 1998; 42 (4) : 485-490 BIOLOGICAL EFFICACY AND PLASMA NORETHISTERONE LEVELS OF ORALLY ADMINISTERED NORETHISTERONE ENANTHATE IN RAT AND HAMSTER P. RAVINDER, K. MADHAVAN NAIR AND B. SIVAKUMAR* Division of Biophysics. National Institute of Nutrition. (Indian Council of Medical Research) Jamai-Osmania, Hyderabad - 500 007 (Received on September 11, 1997) Abstract: Norethisterone enanthate (NET-En) is a well known intramuscular contraceptive drug. The long acting nature of this prep~ration when administered orally was evalu~ted in female rats and hamsters using fertility inhibition test and from the plasma levels of norethisterone (NET). An oral dose of 20-60 mg NET-En was administered to random groups of six female rats and hamsters and were mated after five and ten days with males of proven fertility. The fertility inhibition rate was determined from vaginal delivery. A dose-dependent reduction in fertility was seen in rats 5 days after oral administration of NET-En. This effect was found to be less pronounced and not significant 10 days after administration of similar doses of NET-En. In hamsters, a similar but less pronounced effect was noted. The decrease in fertility was significant only at the 60 mg dose. The plasma levels of NET estimated by RIA over a period of 15 days, in a different set of treated rats, suggested rapid absorption of NET-En within a day, and drug concentration decreased slowly, the levels on the 4th day ranged from 0.9-2.3 with the 10 mg and 1.0-4.0 ng/ml with the 20 mg dose. -
Sports Drug Testing and Toxicology TOP ARTICLES SUPPLEMENT
Powered by Sports drug testing and toxicology TOP ARTICLES SUPPLEMENT CONTENTS REVIEW: Applications and challenges in using LC–MS/MS assays for quantitative doping analysis Bioanalysis Vol. 8 Issue 12 REVIEW: Current status and recent advantages in derivatization procedures in human doping control Bioanalysis Vol. 7 Issue 19 REVIEW: Advances in the detection of designer steroids in anti-doping Bioanalysis Vol. 6 Issue 6 Review For reprint orders, please contact [email protected] 8 Review 2016/05/28 Applications and challenges in using LC–MS/MS assays for quantitative doping analysis Bioanalysis LC–MS/MS is useful for qualitative and quantitative analysis of ‘doped’ biological Zhanliang Wang‡,1, samples from athletes. LC–MS/MS-based assays at low-mass resolution allow fast Jianghai Lu*,‡,2, and sensitive screening and quantification of targeted analytes that are based on Yinong Zhang1, Ye Tian2, 2 ,2 preselected diagnostic precursor–product ion pairs. Whereas LC coupled with high- Hong Yuan & Youxuan Xu** 1Food & Drug Anti-doping Laboratory, resolution/high-accuracy MS can be used for identification and quantification, both China Anti-Doping Agency, 1st Anding have advantages and challenges for routine analysis. Here, we review the literature Road, ChaoYang District, Beijing 100029, regarding various quantification methods for measuring prohibited substances in PR China athletes as they pertain to World Anti-Doping Agency regulations. 2National Anti-doping Laboratory, China Anti-Doping Agency, 1st Anding Road, First draft submitted: -
Microbial Transformation of Bile Acids. a Unified Scheme for Bile Acid Degradation and Hydroxylation of Bile Acids
SR P T03 Form 3 CONDITIONAL THE UNIVERSITY OF NEW SOUTH WALES DECLARATION RELATING TO DISPOSITION OF PROJECT REPORT/THESIS This is to certify that I d?..^ ...being a candidate for the degree of am fully aware of the policy of the University relating to the retention and use of higher degree project reports and theses, namely that the University retains the copies submitted for examination and is free to allow them to be consulted or borrowed. Subject to the provisions of the Copyright Act, 1968, the University may issue a project report or thesis in whole or in part, in photostat or microfilm or other copying medium. I wish the following condition to attach to the use of my project f^pert/thesis: . \ ^-ri pi^^fM-i oA ...-to. .m.P^^.E d .v ^y ^ Ci^^k ^ S.t 01- ^ ^sos-. ^ .TTlk^.f^ u QMIT^. ^L.J^ I also authorize the publication by University Microfilms of a 350 word abstract in Dissertation Abstracts International (applicable to doctorates only). Witness... ..e GENETIC MANIPULATION OF PSEUDOMONADS TO PRODUCE STEROID CATABOLITES FROM BILE ACIDS. A THESIS SUBMriTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF NEW SOUTH WALES AUSTRALIA BY JOHN ALTON IDE SCHOOL OF BIOTECHNOLOGY MAY, 1989. UNIVERSITY OF N.S.W. 16 MAY 1990 CONTENTS Page ABSTRACT i DECLARATION iii ACKNOWLEDGEMENTS iv LIST OF PUBLICATIONS v LIST OF TABLES vi LIST OF FIGURES viii ABBREVIATIONS xi 1 INTRODUCTION 1 LI INTRODUCTION TO STEROID PRODUCTION. 1 L2. EARLY SYNTHETIC PROCESSES FOR THE MANUFACTURE OF STEROID DRUGS. 4 L3. CURRENT PROCESSES 8 L4. -
Epidemiology of Abnormal Uterine Bleeding 25 Michael Zinger 5
Modern Management…Uterine Bleeding rev2:Modern Management…Uterine Bleeding rev2 9/1/08 10:24 Page 1 Modern Management of O’Donovan O’Donovan ABNORMAL • UTERINE BLEEDING Miller Modern Management of Modern Management of Abnormal Uterine Bleeding is written by an internationally recognized team of experts – many of whom are at the forefront of developing 'second-generation' endometrial ablation techniques as well as ABNORMAL UTERINE BLEEDING Modern Management of standard practice. The book covers the full range of surgical and medical treatments, including the background, diagnosis and treatment. ABNORMAL This must have book will help gynecologists refine their operative techniques and consider new approaches to this highly challenging condition. UTERINE BLEEDING Edited by Peter Joseph O`Donovan FRCOG FRCS (ENG) Consultant Gynaecologist and Gynaecological Cancer Lead Director MERIT Centre, Bradford Teaching Hospitals NHS Trust, Bradford and Professor of Medical Innovation, Bradford University, Bradford,UK Charles E Miller MD FACOG Director of Minimally Invasive Gynecologic Surgery, Lutheran General Hospital, Park Ridge, and Clinical Associate Professor, Department of Obstetrics and Gynecology, University of Chicago, and Clinical Associate Professor, Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, IL, USA Cover illustration: ‘The Uterine’ by Elizabeth Gray © UK 2008 Edited by ISBN 978-0-415-45479-7 Peter Joseph O’Donovan www.informahealthcare.com 9 78041 5 454797 Charles Miller MODERN MANAGEMENT OF ABNORMAL -
Tissue Steroid Levels in Response to Reduced Testicular Estrogen Synthesis in the Male Pig, Sus
1 Tissue steroid levels in response to reduced testicular estrogen synthesis in the male pig, Sus 2 scrofa 3 Heidi Kucera1, Birgit Puschner1, Alan Conley2, Trish Berger3* 4 5 1 Department of Molecular Biosciences, School of Veterinary Medicine, University of California, 6 Davis, CA 7 2 Department of Population Health and Reproduction, School of Veterinary Medicine, University 8 of California, Davis, CA 9 3 Department of Animal Science, College of Agricultural and Environmental Sciences, 10 University of California, Davis, CA 11 12 Short title: Estrogen sulfates, aromatase activity and free estrogen concentrations in prostate, 13 testis and liver 14 15 * Corresponding author 16 E-mail: [email protected] (TB) 17 1 18 Abstract 19 Production of steroid hormones is complex and dependent upon steroidogenic enzymes, 20 cofactors, receptors, and transporters expressed within a tissue. Collectively, these factors create 21 an environment for tissue-specific steroid hormone profiles and potentially tissue-specific 22 responses to drug administration. Our objective was to assess steroid production, including 23 sulfated steroid metabolites in the boar testis, prostate, and liver following inhibition of 24 aromatase, the enzyme that converts androgen precursors to estrogens. Boars were treated with 25 the aromatase inhibitor, letrozole from 11 to 16 weeks of age and littermate boars received the 26 canola oil vehicle. Steroid profiles were evaluated in testes, prostate, and livers of 16, 20, and 40 27 week old boars using liquid chromatography/mass spectrometry. Testis, prostate, and liver had 28 unique steroid profiles in vehicle-treated animals. Only C18 steroid hormones were altered by 29 treatment with the aromatase inhibitor, letrozole; no significant differences were detected in any 30 of the C19 or C21 steroids evaluated.